الصفحة الرئيسية>>GPI-16552

GPI-16552 (Synonyms: N-bis-(3-Phenyl-propyl)-9-oxo-fluorene-2,7-diamide)

رقم الكتالوجGB40221

GPI-16552 (443794-40-9) is a novel potent inhibitor of poly(ADP-ribose) glycohydrolase (PARG), IC50=1.7 μM. Pre or post ischemia treatment (40 mg/kg) with GPI-16552 reduces brain infarct volumes in a rat model of cerebral ischemia. It modulates the inflammatory response to ischemia/reperfusion in a rat splanchnic artery occlusion model and reduces the degree of spinal cord inflammation and tissue injury after experimental spinal cord trauma. GPI-16552 synergizes with temozolomide in decreasing melanoma cell invasion and metastatic spreading in mice injected with B16 melanoma cells.

Products are for research use only. Not for human use. We do not sell to patients.

GPI-16552 التركيب الكيميائي

Cas No.: 443794-40-9

الحجم السعر المخزون الكميّة
5mg
180٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

GPI-16552 (443794-40-9) is a novel potent inhibitor of poly(ADP-ribose) glycohydrolase (PARG), IC50=1.7 μM. Pre or post ischemia treatment (40 mg/kg) with GPI-16552 reduces brain infarct volumes in a rat model of cerebral ischemia. It modulates the inflammatory response to ischemia/reperfusion in a rat splanchnic artery occlusion model and reduces the degree of spinal cord inflammation and tissue injury after experimental spinal cord trauma. GPI-16552 synergizes with temozolomide in decreasing melanoma cell invasion and metastatic spreading in mice injected with B16 melanoma cells.

مراجعات

Review for GPI-16552

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for GPI-16552

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.